To report the relationship between gut dysbiosis and interstitial lung disease (ILD) through various scientific approaches, including pathogenesis, metagenomics, and treatment strategies.
Key Findings:
IPF is associated with altered lung microbiome diversity and higher bacterial burden, correlating with disease progression and mortality, indicating a potential target for therapeutic intervention.
Fungal dysbiosis may serve as a biomarker for sarcoidosis, with specific genera linked to disease progression, suggesting avenues for diagnostic exploration.
Gut-lung dysbiosis is implicated in CTD-ILD, with alterations in gut microbiota contributing to lung inflammation, highlighting the need for targeted therapies.
Interpretation:
The microbiome's role in ILD is complex, involving interactions between genetic factors, such as specific gene mutations, environmental triggers like pollution, and microbial antigens.
Limitations:
The relationship between microbiome changes and ILD pathogenesis is not fully understood, particularly the mechanisms of interaction.
Cause and effect in dysbiosis research remains unclear, necessitating further longitudinal studies.
Conclusion:
Microbiome profiling and targeted treatments may enhance diagnostic accuracy and therapeutic outcomes in ILD, potentially leading to personalized medicine approaches.
